Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.
Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in futur
Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch biotech and cueing up a third trial of their immuno-oncology combina